Showing results (461-470 of 782) with videos related to
Sort By:
Pageof 79
Blood|July 16, 2005
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myelomaPaul Gerard Guy Richardson, Bart Barlogie, James Berenson, et al.Cancer Letters|October 15, 2013
Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulationFengjuan Fan, Giovanni Tonon, Muhammad Hasan Bashari, et al.Leukemia|April 10, 2019
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myelomaYan Song, Paul M C Park, Lei Wu, et al.Blood|September 27, 2003
Immunomodulatory drug costimulates T cells via the B7-CD28 pathwayRichard LeBlanc, Teru Hideshima, Laurence P Catley, et al.British Journal of Haematology|May 30, 2018
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 studySundar Jagannath, Jacob Laubach, Ellice Wong, et al.Blood|March 10, 2009
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implicationsTeru Hideshima, Dharminder Chauhan, Tanyel Kiziltepe, et al.Nature Communications|January 17, 2014
Heterogeneity of genomic evolution and mutational profiles in multiple myelomaNiccolo Bolli, Hervé Avet-Loiseau, David C Wedge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivoTeru Hideshima, Paola Neri, Pierfranchesco Tassone, et al.Cancer|February 4, 2005
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal functionSundar Jagannath, Bart Barlogie, James R Berenson, et al.Plos One|July 14, 2011
Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translationDouglas W McMillin, Jake Delmore, Joseph Negri, et al.Pageof 79